

From: [REDACTED]
To: [ETF SMB Board Feedback](#)
Subject: Adding anti-obesity medications to the State of Wisconsin Group Health Insurance Program
Date: Friday, April 28, 2023 7:49:27 AM
Attachments: [AOM letter.pdf](#)

**CAUTION: This email originated from outside the organization.
Do not click links or open attachments unless you recognize the sender and know the content is safe.**

April 27, 2023

The Group Insurance Board (GIB)
ETFSMBBoardFeedback@etf.wi.gov

RE: Adding anti-obesity medications to the State of Wisconsin Group Health Insurance Program

To whom it may concern:

As a board-certified physician, public employee and insurance plan member, I am writing to request consideration of adding anti-obesity medications to the State of Wisconsin Group Health Insurance Program. As you know, obesity is a chronic progressive disease that affects over 40% of adults in Wisconsin and a leading cause of preventable death worldwide. While obesity can be notoriously difficult to treat, anti-obesity medications (AOMs) are now viable treatment options, which have been shown to increase an individual's weight loss over time as part of a comprehensive weight management program.

Adding AOMs to the state health insurance program may lead to numerous benefits for members, such as improved health outcomes, quality of life, and productivity. Providing access to AOMs may not only improve members' weight loss but lower their risk of chronic conditions like type 2 diabetes, heart disease, osteoarthritis, and certain types of cancer. AOMs may also help members decrease or even stop other medications used to treat common obesity-related comorbidities, such as high blood pressure and hyperlipidemia. Further, by helping state insurance plan members manage their weight, AOMs may improve their quality of life and enhance their self-esteem and mobility.

Allowing AOMs with prior authorization to be covered by etf medical insurance plans will provide another affordable option for members needing to lose weight and manage their chronic disease. This step will also allow more equitable access to AOMs and show members that the State of Wisconsin benefit plans meet their needs. All our neighboring states (Minnesota, Iowa, Illinois, Indiana, and Michigan) offer AOMs as a benefit to their public employees. The Wisconsin Medicaid program also offers AOMs as a benefit to their recipients. I am asking the Group Insurance Board to add AOMs to the State of Wisconsin Group Health Insurance Program as well.

Thank you for your consideration.

Sincerely,

Michelle Kelly, MD, PhD
Employee, University of Wisconsin School of Medicine and Public Health

April 27, 2023

The Group Insurance Board (GIB)
ETFSMBBoardFeedback@etf.wi.gov

RE: Adding anti-obesity medications to the State of Wisconsin Group Health Insurance Program

To whom it may concern:

As a board-certified physician, public employee and insurance plan member, I am writing to request consideration of adding anti-obesity medications to the State of Wisconsin Group Health Insurance Program. As you know, obesity is a chronic progressive disease that affects over 40% of adults in Wisconsin and a leading cause of preventable death worldwide. While obesity can be notoriously difficult to treat, anti-obesity medications (AOMs) are now viable treatment options, which have been shown to increase an individual's weight loss over time as part of a comprehensive weight management program.

Adding AOMs to the state health insurance program may lead to numerous benefits for members, such as improved health outcomes, quality of life, and productivity. Providing access to AOMs may not only improve members' weight loss but lower their risk of chronic conditions like type 2 diabetes, heart disease, osteoarthritis, and certain types of cancer. AOMs may also help members decrease or even stop other medications used to treat common obesity-related comorbidities, such as high blood pressure and hyperlipidemia. Further, by helping state insurance plan members manage their weight, AOMs may improve their quality of life and enhance their self-esteem and mobility.

Allowing AOMs with prior authorization to be covered by etf medical insurance plans will provide another affordable option for members needing to lose weight and manage their chronic disease. This step will also allow more equitable access to AOMs and show members that the State of Wisconsin benefit plans meet their needs. All our neighboring states (Minnesota, Iowa, Illinois, Indiana, and Michigan) offer AOMs as a benefit to their public employees. The Wisconsin Medicaid program also offers AOMs as a benefit to their recipients. I am asking the Group Insurance Board to add AOMs to the State of Wisconsin Group Health Insurance Program as well.

Thank you for your consideration.

Sincerely,



Michelle Kelly, MD, PhD
Employee, University of Wisconsin School of Medicine and Public Health



STATE OF WISCONSIN
Department of Employee Trust Funds
A. John Voelker
SECRETARY

Wisconsin Department
of Employee Trust Funds
PO Box 7931
Madison WI 53707-7931
1-877-533-5020 (toll free)
Fax 608-267-4549
etf.wi.gov

May 1, 2023

Michelle Kelly
[REDACTED]

Dear Michelle Kelly:

Thank you for your email to the Group Insurance Board (Board) regarding adding coverage of anti-obesity medications (AOMs) to the Group Health Insurance Program (GHIP).

The Board has discussed adding AOMs to the pharmacy formulary in the past. The Board cannot add coverage for benefits that are not mandated by law unless savings can be demonstrated or benefits are reduced (see [Wis. Stats. § 40.03\(6\)\(c\)](#)). The Board reviewed coverage of AOMs through the pharmacy benefit at the June 30, 2022, meeting. As noted in the [“Weight-Loss Drug Coverage Options Review”](#) memo, the Board’s actuary, Segal, estimated the cost of adding weight-loss drugs to the Board’s non-Medicare formulary would be about \$11,000 to \$13,000 per person, or between \$12 million–\$17 million per year. The most recently-available studies produced on these drugs report they are only estimated to save about \$1,400 per patient per year or about \$2 million a year in savings. This was one of the reasons the Board was not able to add coverage.

Another reason the Board is hesitant to add coverage is that the long-term effects of taking AOMs for multiple years is unknown and studies are currently being conducted. AOM drug manufacturers have conducted studies of the short-term effects of taking AOMs for up to 72 weeks. However, most research has shown that patients will be on AOMs for multiple years and, in some cases, possibly the rest of their lives. Long-term studies of AOMs aim to answer the questions of whether weight regain may occur over time despite continued therapy, if maintaining weight loss is viable under the drug, and the good and bad health effects of taking weight-loss drugs for a long duration. The timelines and release dates of the information from these ongoing studies are unknown.

GHIP members can obtain some AOMs, such as Wegovy and Saxenda, at a discounted rate. The drugs on the attached “Department of Employee Trust Funds Discount Drug List” are not covered by the GHIP’s pharmacy benefit but can be obtained at the negotiated rate Navitus Health Solutions, the Board’s Pharmacy Benefit Manager (PBM), has with the pharmacy filling the drug prescription. The pharmacy negotiated

Michelle Kelly

May 1, 2023

Page 2

rate will be lower than the full price of the drug. Please note that the price a member pays will not count towards any out-of-pocket limits (OOPL) or any pharmacy deductible.

In your email, you observed that some state employees in neighboring states do have coverage of AOMs, which is correct. However, that coverage varies, and often other requirements must be met. For example, a Minnesota State employee must pay the full cost of AOMs for three months and lose five percent of their body weight before the Minnesota State pharmacy benefit would start to pay for the AOM. These requirements significantly limit the number of Minnesota State Employees who take weight-loss drugs.

During the February 22, 2023, Board meeting, the Board received a ["2024 Preliminary Agreement and Benefit Changes"](#) memo and presentation regarding possible health insurance and pharmacy benefit changes for 2024. Coverage of weight-loss drugs is discussed in that memo.

At the upcoming May 17, 2023, Board meeting, ETF staff will present the Board with their findings regarding preliminary changes, including the addition of weight-loss drug coverage for 2024. The May meeting agenda, Board memos, and other materials will be posted to the ETF website on the ["Group Insurance Board Meeting Agendas and Materials"](#) page before the meeting.

Again, thank you for your email. If you have any other questions, comments, or concerns, please do not hesitate to contact me using the information below.

Sincerely,

Tricia Sieg, Pharmacy Benefits Program Manager

Office of Strategic Health Policy

Department of Employee Trust Funds

tricia.sieg@etf.wi.gov

608-261-6006

Department of Employee Trust Funds Discount Drug List

Updated January 2023

Prescriptions that are not covered by your pharmacy benefit may be available at a discounted rate. This may include drugs for infertility, weight loss, cosmetic or other lifestyle needs as prescribed by your doctor. You can use your Health Care Flexible Spending account to pay for them, with a prescription.

DRUG	Copay	Drug Category
ADIPEX-P CAP	100%	WEIGHT LOSS
ADIPEX-P TAB	100%	WEIGHT LOSS
AVAGE CREAM	100%	COSMETICS
CAVERJECT INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
cetorelix acetate for inj kit	100%	INFERTILITY, INJECTABLES
CETROTIDE INJ KIT	100%	INFERTILITY, INJECTABLES
CHROMELIN SOLN	100%	COSMETICS
CLOMID TAB, CLOMIPHENE CITRATE TAB	100%	INFERTILITY
CLOMIPHENE CITRATE POWDER	100%	INFERTILITY
CONTRACE TAB	100%	WEIGHT LOSS
DY-O-DERM SOLN	100%	COSMETICS
EDEX INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
finasteride tab	100%	COSMETICS
FOLLISTIM AQ INJ	100%	INFERTILITY, INJECTABLES
ganirelix ac inj	100%	INFERTILITY, INJECTABLES
GONAL-F RFF INJ	100%	INFERTILITY, INJECTABLES
hydroquinone cream	100%	COSMETICS
leuprolide inj	100%	INFERTILITY, INJECTABLES
LUPRON DEPOT INJ	100%	INJECTABLES
LUSTRA CREAM	100%	COSMETICS
MENOPUR INJ	100%	INFERTILITY, INJECTABLES
METHOXSALEN POWDER	100%	COSMETICS
minoxidil soln	100%	COSMETICS
MUSE SUPP	100%	SEXUAL DYSFUNCTION
OVIDREL INJ	100%	INFERTILITY, INJECTABLES
PAPAVERINE/ALPROSTADIL INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
PAPAVERINE/PHENTOLAMINE INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
PAPAVERINE/PHENTOLAMINE/ALPROSTADIL INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
phentermine cap	100%	WEIGHT LOSS
phentermine tab	100%	WEIGHT LOSS
PHENTOLAMINE/ALPROSTADIL INJ	100%	INJECTABLES, SEXUAL DYSFUNCTION
PREGNYL INJ	100%	INFERTILITY

PROPECIA TAB	100%	COSMETICS
QSYMIA CAP	100%	WEIGHT LOSS
RENOVA CREAM	100%	COSMETICS
ROGAINE SOLN	100%	COSMETICS
SAXENDA INJ	100%	INJECTABLES, WEIGHT LOSS
sildenafil tab	100%	SEXUAL DYSFUNCTION
STENDRA	100%	SEXUAL DYSFUNCTION
tadalafil tab	100%	SEXUAL DYSFUNCTION
TRELSTAR INJ	100%	INFERTILITY, INJECTABLES
TRI-LUMA CREAM	100%	COSMETICS
VANIQA CREAM	100%	COSMETICS
varденаfil ODT	100%	SEXUAL DYSFUNCTION
varденаfil tab	100%	SEXUAL DYSFUNCTION
VITADYE LOTION	100%	COSMETICS
WEGOVY INJ	100%	INJECTABLES, WEIGHT LOSS
WEGOVY INJ 1.7MG/0.75ML	100%	INJECTABLES, WEIGHT LOSS
WEGOVY INJ 2.4MG/0.75ML	100%	INJECTABLES, WEIGHT LOSS
XENICAL CAP	100%	WEIGHT LOSS